[go: up one dir, main page]

WO2010080935A8 - Monoclonal antibodies against pcbp-1 antigens, and uses therefor - Google Patents

Monoclonal antibodies against pcbp-1 antigens, and uses therefor Download PDF

Info

Publication number
WO2010080935A8
WO2010080935A8 PCT/US2010/020401 US2010020401W WO2010080935A8 WO 2010080935 A8 WO2010080935 A8 WO 2010080935A8 US 2010020401 W US2010020401 W US 2010020401W WO 2010080935 A8 WO2010080935 A8 WO 2010080935A8
Authority
WO
WIPO (PCT)
Prior art keywords
pcbp
antigens
antibodies
present
monoclonal antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/020401
Other languages
French (fr)
Other versions
WO2010080935A1 (en
Inventor
Ozge Alper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alper Biotech LLC
Original Assignee
Alper Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alper Biotech LLC filed Critical Alper Biotech LLC
Priority to EP10700041A priority Critical patent/EP2421900A1/en
Publication of WO2010080935A1 publication Critical patent/WO2010080935A1/en
Publication of WO2010080935A8 publication Critical patent/WO2010080935A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens.
PCT/US2010/020401 2009-01-11 2010-01-07 Monoclonal antibodies against pcbp-1 antigens, and uses therefor Ceased WO2010080935A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10700041A EP2421900A1 (en) 2009-04-24 2010-01-07 Monoclonal antibodies against pcbp-1 antigens, and uses therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2060109P 2009-01-11 2009-01-11
US61/020,601 2009-01-11
US17245709P 2009-04-24 2009-04-24
US61/172,457 2009-04-24

Publications (2)

Publication Number Publication Date
WO2010080935A1 WO2010080935A1 (en) 2010-07-15
WO2010080935A8 true WO2010080935A8 (en) 2010-10-14

Family

ID=41785596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/020401 Ceased WO2010080935A1 (en) 2009-01-11 2010-01-07 Monoclonal antibodies against pcbp-1 antigens, and uses therefor

Country Status (1)

Country Link
WO (1) WO2010080935A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2596365A4 (en) 2010-07-14 2013-12-18 Alper Biotech Llc MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS AND USES THEREOF
ITFI20120122A1 (en) * 2012-06-15 2013-12-16 Kedrion S P A 50 MONOCLONAL ANTIBODIES THAT CAN TIE THE E2 VIRAL PROTEIN PREPARATION AND USE.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1775590A1 (en) * 2005-10-11 2007-04-18 Laboratorios S.A.L.V.A.T., S.A. Non-invasive in vitro method to detect transitional cell carcinoma of the bladder
JP5014780B2 (en) * 2006-12-28 2012-08-29 株式会社先端生命科学研究所 Method for immunological analysis of methylated heterogeneous nuclea ribonucleoprotein and use thereof

Also Published As

Publication number Publication date
WO2010080935A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
JOP20180042A1 (en) Humanized Antigen-Binding Domains and Methods of Use
JOP20190002A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
WO2011127412A3 (en) Soluble human st-2 antibodies and assays
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
MX2013006428A (en) Tnf-a binding proteins.
WO2007109321A3 (en) Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2010102276A3 (en) Humanized anti-cd19 antibody formulations
MX369148B (en) Kir3dl2 binding agents.
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013037484A3 (en) Anti-aplhabetatcr antibody
WO2010121093A3 (en) Humanized antibody compositions and methods for binding lysophosphatidic acid
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
IN2012DN02634A (en)
TN2013000076A1 (en) Anti-ox40 antibodies and methods of using the same
WO2013188864A3 (en) Anti-cd22 anti-idiotypic antibodies and uses thereof
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
IL186948A0 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
ZA202008095B (en) Humanized antibodies against psma
WO2013138244A3 (en) Treatment of multiple sclerosis with anti-cd19 antibody
WO2020223392A3 (en) Cancer associated antibody compositions and methods of use
MY210018A (en) Monoclonal antibody that binds specifically to gitr
ZA202308896B (en) Antibodies binding trop2 and uses thereof
WO2012051282A3 (en) Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy
WO2014016702A3 (en) Humanized forms of monoclonal antibodies to human gnrh receptor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10700041

Country of ref document: EP

Kind code of ref document: A1

WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Ref document number: 61/020,601

Country of ref document: US

Date of ref document: 20100817

Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010700041

Country of ref document: EP